Erudio Healtherudio.com
Drug
Intismeran autogene trials: what clinicians said in public
HCP commentary reports on 2 clinical trials studying intismeran autogene: INTerpath-002 and INTerpath-009. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 5 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| INTerpath-009 NCT06623422 · Merck Sharp & Dohme LLC | resectable stage II–IIIB (N2) NSCLC not achieving pCR | Phase 3 | 82 | 18 | Focused | Oct 31, 2026 | Preview |
| INTerpath-002 NCT06077760 · Merck Sharp & Dohme LLC | resected stage II–IIIB (N2) non-small cell lung cancer | Phase 3 | 36 | 19 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| INTerpath-001 NCT05933577 · Merck Sharp & Dohme LLC DeepView → | high-risk stage II-IV melanoma | Phase 3 | Deep | View | |||
| INTerpath-004 NCT06307431 · Merck Sharp & Dohme LLC DeepView → | adjuvant treatment of renal cell carcinoma | Phase 2 | Deep | View | |||
| INTerpath-005 NCT06305767 · Merck Sharp & Dohme LLC DeepView → | muscle-invasive urothelial carcinoma | Phase 1/Phase 2 | Deep | View | |||
| INTerpath-007 NCT06295809 · Merck Sharp & Dohme LLC FocusedView → | resectable locally advanced cutaneous squamous cell carcinoma | Phase 2/Phase 3 | Focused | View | |||
| INTerpath-13 NCT07221474 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 2 | Focused | View | |||